Table 6.
Utirik adult body burdens, 1979 (D = ratio-derived; NA = not
analyzed).
Males
Body
burden
(uci)
Females
Number
of
. persons
Body
burden
(wi)
-
All adults
Number
of
persons
_ Body
burden
( Wi)
Number
of
persons
Days
post
return
606,
D
D
4.0x1073
9.7x1074
550
3.5x1071*
2:7x1071
3.7x1072
D
3.1x1073
7.6x1074
2
14
3.5x1073
8.7x1074
1.6x1l071
3.3x1072
15
2.1x1071
3.5x1l072
2464
3924
29
1734
2464
55 ie
D
1.7x1071
1.6x107!
1.6x107!
6114
90,
1.4x1073
5
2.4x1073
2
1.7x1073
NA
1.5x1074
12
14
NA
1.5xl074
12
17
NA
1.5x1074
24
31
8669
9225
4.1x1071
NA
2.7x1071
NA
3.3x1071
NA
1004
2.6x107!
9
1.3x107!
13
1.8x107!
22
7213
1.2x1073
13765
2.9x1071
1.2x1071
6.2x1072
5
15
27
19
1.3x1073
2.0x107!
6
7.8x1072
4.3x1072
15
21
17
1.3x1079
2.5x1071
1.0x107!
5.3x1072
7
11
30
48
36
1734
7213
1734
8309
9225
*Measured at Argonne, not used in dosimetry.
tod
C33
a7
C23
co
CF
90sr, and 137¢s. The standard deviation on this ratio is 15%. These ratios
were determined only when the body burden for the nuclide of interest had
reached a maximum. Thus a significant time passed on Rongelap, 2 to 3 years
post return, before a body burden comparison was valid.
It was observed, in all cases, that the population mean body burdens
were lower by a factor of 3 than the highest for any individual in the population. The population mean dose equivalent and maximum dose equivalent likewise differed by a factor of 3. The population average daily activity inges~
tion rate and maximum value differed by a factor of 4. For the nuclides 37¢s
and 6>2n, a substantial sub-group in the population, children and infants,
received a dose equivalent higher than the population mean value.
- 118 -